IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Shaughnessy, J.

ART UNIT:

§

§

FILED: December 04, 2003

EXAMINER:

SERIAL NO.: 10/727,461

DOCKET:

FOR: Identification of Molecular Determinants

D6485

of Myeloma Bone Disease Ş

Commissioner of Patents P.O. Box 1450 MS DD Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Dear Sir:

Enclosed herewith for filing under 37 C.F.R. 1.97(b) in the above-referenced matter is form PTO-1449 together with copies of the references listed therein. If any questions remain, the Examiner is respectfully requested to call the undersigned attorney at (713)-270-5391.

Respectfully submitted,

ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071

(713) 270-5391

BADLER1@houston.rr.com

Benjamin Aaron Adler, Ph.D.,J.D.

Registration No. 35,423 Counsel for Applicant

JUN 1 7 2004

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Information Disclosure

DOCKET NO.: **SERIAL NO.:**

D6485 10/727,461

Statement

APPLICANT: FILING DATE:

Shaughnessy, John D December 04, 2003

GROUP:

U.S. PATENT DOCUMENTS

Examiner

Document

Date Name

Class

Subclass

Filing Date

Initial

Number

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Publication: Patent Cooperation Treaty (PCT)

Translation: English

Document Number:20040038860

Date: 2/26/04

Country: Great Britain

Class Or Subclass

A61K 038/45

Patent: Yes No X

Title: Reagents and Methods for Modulating dkk-Mediated Interactions

OTHER DOCUMENTS (Including Author, Title, Place of Date, Publication)

a. Zhang, Y. et al. The LRP5 High-Bone-Mass G171 Mutation Disrupts LRP5 Interaction with Mesd: Molecular and Cellular Biology, June 2004, vol. 24, no. 11, pp. 4677-4684

b. Boyden, L. M. et al. High Bone Density Due to a Mutation in LDL-Receptor-Related Protein 5: N Engl J Med, May 16, 2002, vol. 346, no. 20, pp. 1513-1521

c. Little, R.D. et al.; A Mutation in the LDL Receptor-Related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait: Am. J. Hum. Genet., 2002 vol. 70, pp. 11-19

Examiner |

Date Considere

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

JUN 1 7 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Shaughnessy, J.

ART UNIT:

FILED: December 04, 2003

§

§

EXAMINER:

SERIAL NO.: 10/727,461

FOR: Identification Molecular Determinants

§

DOCKET:

Of Myeloma Bone Disease

D6485

Commissioner of Patents P.O. Box 1450 MS DD Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

Dear Sir:

I hereby certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is to: Commissioner of Patents, BOX DD, Alexandria, VA addressed 22313.

- 1) Information Disclosure Statement;
- 2) Information Disclosure Statement Cover Letter;
- PTO Form 1449 (Four References cited); and 3)
- 4) Postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071

(713) 270-5391

BADLER1@houston.rr.com

Respectfully submitted,

Behjamin Aaron Adler, Ph.D., J.D.

Registration No. 35,423

Counsel for Applicant